$MBIO
MUSTANG BIO, INC.

2023 Q4 Form 10-K Financial Statement

#000155837024002899 Filed on March 11, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.179M $9.686M
YoY Change -9.02% -20.67%
% of Gross Profit
Research & Development $6.377M $40.51M
YoY Change -60.97% -35.15%
% of Gross Profit
Depreciation & Amortization $284.0K $1.900M
YoY Change -60.99% -29.63%
% of Gross Profit
Operating Expenses $8.856M $49.26M
YoY Change -54.43% -35.32%
Operating Profit -$49.26M
YoY Change -35.32%
Interest Expense $126.0K -$3.259M
YoY Change -115.05% 22.06%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$2.342M
YoY Change -100.16% 71.45%
Pretax Income -$8.616M -$51.60M
YoY Change -56.12% -33.44%
Income Tax
% Of Pretax Income
Net Earnings -$8.616M -$51.60M
YoY Change -56.12% -33.44%
Net Earnings / Revenue
Basic Earnings Per Share -$6.00
Diluted Earnings Per Share -$0.86 -$6.00
COMMON SHARES
Basic Shares Outstanding 8.604M
Diluted Shares Outstanding 8.604M

Balance Sheet

Concept 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.234M $6.234M
YoY Change -91.76% -91.76%
Cash & Equivalents $6.234M $6.234M
Short-Term Investments
Other Short-Term Assets $1.233M $1.233M
YoY Change -60.98% -60.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.35M $11.35M
YoY Change -85.61% -85.61%
LONG-TERM ASSETS
Property, Plant & Equipment $3.218M $4.813M
YoY Change -65.73% -60.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $833.0K $1.583M
YoY Change 219.16% 25.54%
Total Long-Term Assets $6.396M $6.396M
YoY Change -52.87% -52.87%
TOTAL ASSETS
Total Short-Term Assets $11.35M $11.35M
Total Long-Term Assets $6.396M $6.396M
Total Assets $17.74M $17.74M
YoY Change -80.8% -80.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.322M $6.322M
YoY Change -7.48% -7.48%
Accrued Expenses $8.310M $8.310M
YoY Change 8.94% 8.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.37M $15.37M
YoY Change 1.73% 1.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $2.248M $2.248M
YoY Change -37.62% -37.62%
Total Long-Term Liabilities $2.248M $2.248M
YoY Change -92.76% -92.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.37M $15.37M
Total Long-Term Liabilities $2.248M $2.248M
Total Liabilities $17.62M $17.62M
YoY Change -61.82% -61.82%
SHAREHOLDERS EQUITY
Retained Earnings -$381.0M
YoY Change 15.66%
Common Stock $380.5M
YoY Change 1.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.0K $123.0K
YoY Change
Total Liabilities & Shareholders Equity $17.74M $17.74M
YoY Change -80.8% -80.8%

Cashflow Statement

Concept 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$8.616M -$51.60M
YoY Change -56.12% -33.44%
Depreciation, Depletion And Amortization $284.0K $1.900M
YoY Change -60.99% -29.63%
Cash From Operating Activities -$7.254M -$49.48M
YoY Change -52.55% -23.96%
INVESTING ACTIVITIES
Capital Expenditures $30.00K $64.00K
YoY Change -68.42% -97.64%
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.950M
YoY Change -100.0% -2600.0%
Cash From Investing Activities -$30.00K $5.886M
YoY Change -92.86% -299.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.956M -26.08M
YoY Change 395500.0% -176.58%
NET CHANGE
Cash From Operating Activities -7.254M -49.48M
Cash From Investing Activities -30.00K 5.886M
Cash From Financing Activities 3.956M -26.08M
Net Change In Cash -3.328M -69.67M
YoY Change -78.81% 105.15%
FREE CASH FLOW
Cash From Operating Activities -$7.254M -$49.48M
Capital Expenditures $30.00K $64.00K
Free Cash Flow -$7.284M -$49.54M
YoY Change -52.65% -26.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.09
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8604104
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7684508
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001680048
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2034-12-31
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2200000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2796000
CY2023Q1 mbio Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
0.0667
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38191
CY2023 dei Entity Registrant Name
EntityRegistrantName
MUSTANG BIO, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3828760
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
377 Plantation Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Worcester
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01605
CY2023 dei City Area Code
CityAreaCode
781
CY2023 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
MBIO
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
38700000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6234000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75656000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1233000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2897000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11346000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
78852000
CY2023Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
3218000
CY2022Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
8440000
CY2023Q4 mbio Construction In Process Net
ConstructionInProcessNet
29000
CY2022Q4 mbio Construction In Process Net
ConstructionInProcessNet
951000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
833000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
261000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1566000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2918000
CY2023Q4 us-gaap Assets
Assets
17742000
CY2022Q4 us-gaap Assets
Assets
92422000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14017000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13731000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
520000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
612000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15371000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15109000
CY2023Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
270000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
270000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
27436000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1978000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3334000
CY2023Q4 us-gaap Liabilities
Liabilities
17619000
CY2022Q4 us-gaap Liabilities
Liabilities
46149000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
419089
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
187134
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
591000
CY2022Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1109000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380502000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
374522000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-380971000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329369000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
123000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46273000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17742000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92422000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40513000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
62475000
CY2023 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
527000
CY2022 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1474000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1466000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9686000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12210000
CY2023 us-gaap Operating Expenses
OperatingExpenses
49260000
CY2022 us-gaap Operating Expenses
OperatingExpenses
76159000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-49260000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-76159000
CY2023 mbio Grant Income
GrantIncome
917000
CY2022 mbio Grant Income
GrantIncome
1304000
CY2023 us-gaap Interest Income Other
InterestIncomeOther
850000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
689000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
4109000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
3359000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2342000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1366000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-51602000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.09
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8604104
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7684508
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
112400000
CY2022 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
1109000
CY2022 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
6500000
CY2022 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
166000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
206000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2283000
CY2022 mbio Additions To Apic Equity Fees On Rwg Debt
AdditionsToApicEquityFeesOnRwgDebt
750000
CY2022 mbio Additions To Apic From Issuance Of Rwg Debt Warrants
AdditionsToApicFromIssuanceOfRwgDebtWarrants
384000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46273000
CY2023 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
477000
CY2023 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
160000
CY2023 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
4000
CY2023 mbio Stock Issued During Period Value Registered Direct Offering
StockIssuedDuringPeriodValueRegisteredDirectOffering
3955000
CY2023 mbio Stock Issued During Period Value Equity Fee For Registered Direct Offering
StockIssuedDuringPeriodValueEquityFeeForRegisteredDirectOffering
110000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
178000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
568000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-51602000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
123000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-51602000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2023 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
0
CY2022 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
166000
CY2023 mbio Common Shares Issubale Equity Fee On At Market Offering
CommonSharesIssubaleEquityFeeOnAtMarketOffering
4000
CY2022 mbio Common Shares Issubale Equity Fee On At Market Offering
CommonSharesIssubaleEquityFeeOnAtMarketOffering
0
CY2023 mbio Equity Fee On Registered Direct Offering
EquityFeeOnRegisteredDirectOffering
110000
CY2022 mbio Equity Fee On Registered Direct Offering
EquityFeeOnRegisteredDirectOffering
0
CY2023 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
477000
CY2022 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
1109000
CY2023 mbio Issuance Of Common Shares Equity Fee On Notes Payable
IssuanceOfCommonSharesEquityFeeOnNotesPayable
0
CY2022 mbio Issuance Of Common Shares Equity Fee On Notes Payable
IssuanceOfCommonSharesEquityFeeOnNotesPayable
750000
CY2023 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
50000
CY2022 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
365000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
568000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2283000
CY2023 us-gaap Depreciation
Depreciation
1860000
CY2022 us-gaap Depreciation
Depreciation
2723000
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
118000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
470000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
365000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
308000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-255000
CY2023 mbio Gain On Sale Of Property Plant Equipment
GainOnSaleOfPropertyPlantEquipment
1466000
CY2022 mbio Gain On Sale Of Property Plant Equipment
GainOnSaleOfPropertyPlantEquipment
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2796000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 mbio Gain On Lease Modification
GainOnLeaseModification
-220000
CY2022 mbio Gain On Lease Modification
GainOnLeaseModification
0
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1092000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1006000
CY2023 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
125000
CY2022 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
5257000
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
67000
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
43000
CY2023 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
680000
CY2022 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
263000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49477000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65066000
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
365000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
127000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2714000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5886000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2952000
CY2023 us-gaap Repayments Of Debt
RepaymentsOfDebt
30375000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2023 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
163000
CY2022 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
6623000
CY2023 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
3000
CY2022 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
123000
CY2023 mbio Proceeds From Issuance Of Common Shares In Registered Direct Offering
ProceedsFromIssuanceOfCommonSharesInRegisteredDirectOffering
4398000
CY2022 mbio Proceeds From Issuance Of Common Shares In Registered Direct Offering
ProceedsFromIssuanceOfCommonSharesInRegisteredDirectOffering
0
CY2023 mbio Proceeds From Payments For Offering Costs On Issuance Of Common Shares For Registered Direct Offering
ProceedsFromPaymentsForOfferingCostsOnIssuanceOfCommonSharesForRegisteredDirectOffering
-443000
CY2022 mbio Proceeds From Payments For Offering Costs On Issuance Of Common Shares For Registered Direct Offering
ProceedsFromPaymentsForOfferingCostsOnIssuanceOfCommonSharesForRegisteredDirectOffering
0
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
30000000
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2650000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
178000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
206000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26081000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34056000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-69672000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-33962000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76656000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110618000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6984000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76656000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1352000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2710000
CY2023 us-gaap Stock Issued1
StockIssued1
1109000
CY2022 us-gaap Stock Issued1
StockIssued1
4212000
CY2023 mbio Note Payable Payment Incurred But Not Paid
NotePayablePaymentIncurredButNotPaid
0
CY2022 mbio Note Payable Payment Incurred But Not Paid
NotePayablePaymentIncurredButNotPaid
1050000
CY2023 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
384000
CY2023 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
CY2022 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
2176000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-381000000.0
CY2023Q4 mbio Proceeds From Issuance Of Common Shares In Registered Direct Offering
ProceedsFromIssuanceOfCommonSharesInRegisteredDirectOffering
4400000
CY2023Q4 mbio Proceeds From Payments For Offering Costs On Issuance Of Common Shares For Registered Direct Offering
ProceedsFromPaymentsForOfferingCostsOnIssuanceOfCommonSharesForRegisteredDirectOffering
500000
CY2023 mbio Number Of Subsidiaries
NumberOfSubsidiaries
0
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000.0
CY2023Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3299647
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
596235
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
0
CY2016Q3 mbio Preferred Stock Voting Rights Multiplier
PreferredStockVotingRightsMultiplier
1.1
CY2023Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
187134
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7694000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16841000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4476000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8401000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3218000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8440000
CY2023 us-gaap Depreciation
Depreciation
1900000
CY2022 us-gaap Depreciation
Depreciation
2700000
CY2023Q4 mbio Construction In Process Net
ConstructionInProcessNet
29000
CY2022Q4 mbio Construction In Process Net
ConstructionInProcessNet
1000000.0
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6322000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6833000
CY2023Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
4118000
CY2022Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
2782000
CY2023Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
2838000
CY2022Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
3468000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
739000
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
648000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14017000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13731000
CY2022Q2 us-gaap Net Rentable Area
NetRentableArea
26503
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2023Q2 us-gaap Net Rentable Area
NetRentableArea
26503
CY2023Q2 us-gaap Net Rentable Area
NetRentableArea
11916
CY2023Q2 mbio Increase Decrease In Right Of Use Lease Liability
IncreaseDecreaseInRightOfUseLeaseLiability
1000000.0
CY2023Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1200000
CY2023Q2 mbio Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
200000
CY2017Q4 us-gaap Net Rentable Area
NetRentableArea
27043
CY2017Q4 mbio Lessee Operating Lease Total Abatements Over Lease Term
LesseeOperatingLeaseTotalAbatementsOverLeaseTerm
600000
CY2017Q4 mbio Lessee Operating Lease Total Base Rent Net Of Abatements
LesseeOperatingLeaseTotalBaseRentNetOfAbatements
3600000
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2017Q4 mbio Lessee Security Deposit Upon Full Occupancy
LesseeSecurityDepositUponFullOccupancy
1300000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2500000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1600000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3900000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2900000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
439000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
565000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
467000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
488000
CY2023 us-gaap Lease Cost
LeaseCost
906000
CY2022 us-gaap Lease Cost
LeaseCost
1053000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
529000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
485000
CY2023 mbio Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
220000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
723000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
774000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
703000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
269000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
274000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
303000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3046000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
548000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2498000
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
1187000
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
2899000
CY2023 mbio Interest Expense Amortization Of Debt Discount
InterestExpenseAmortizationOfDebtDiscount
118000
CY2022 mbio Interest Expense Amortization Of Debt Discount
InterestExpenseAmortizationOfDebtDiscount
445000
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
9000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
4109000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
3359000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 mbio Sale Of Stock Aggregate Offering Price Permitted By Agreement
SaleOfStockAggregateOfferingPricePermittedByAgreement
4400000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
568000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2283000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
220577
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
120.30
CY2021 mbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P0Y8M23D
CY2022 mbio Class Of Warrant Or Right Warrants Expired During Period
ClassOfWarrantOrRightWarrantsExpiredDuringPeriod
200251
CY2022 mbio Warrant Exercise Price Expired During Period
WarrantExercisePriceExpiredDuringPeriod
127.49
CY2022 mbio Class Of Warrant Or Right Warrants Granted During Period
ClassOfWarrantOrRightWarrantsGrantedDuringPeriod
49869
CY2022 mbio Class Of Warrant Or Right Weighted Average Exercise Price Grants During Period
ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod
12.03
CY2022 mbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P9Y2M4D
CY2023 mbio Class Of Warrant Or Right Warrants Granted During Period
ClassOfWarrantOrRightWarrantsGrantedDuringPeriod
4411766
CY2023 mbio Class Of Warrant Or Right Weighted Average Exercise Price Grants During Period
ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod
1.00
CY2023 mbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P5Y3M14D
CY2023 mbio Employee Stock Purchase Plan Predetermined Offering Period Lower Fair Market Value Percentage
EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage
0.85
CY2023 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
86578
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
380089
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.04
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.05
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.03
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.38
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.42
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
84651000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
75011000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1946000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2399000
CY2023Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2022Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
11856000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13375000
CY2023Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
929000
CY2022Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
1466000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1841000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1434000
CY2023Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
5000
CY2022Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
6000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
18189000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15649000
CY2023Q4 mbio Deferred Tax Assets Capitalization Of Research And Development Expenses
DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
28800000
CY2022Q4 mbio Deferred Tax Assets Capitalization Of Research And Development Expenses
DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
19787000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
148276000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
129186000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
147694000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128101000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
582000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1085000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
582000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1085000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
147700000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128100000
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q4 mbio Deferred Tax Assets Capitalization Of Research And Development Expenses
DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
28800000

Files In Submission

Name View Source Status
0001558370-24-002899-index-headers.html Edgar Link pending
0001558370-24-002899-index.html Edgar Link pending
0001558370-24-002899.txt Edgar Link pending
0001558370-24-002899-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231xex10d28.htm Edgar Link pending
tmb-20231231xex10d29.htm Edgar Link pending
tmb-20231231xex10d29001.jpg Edgar Link pending
tmb-20231231xex10d30.htm Edgar Link pending
tmb-20231231xex23d1.htm Edgar Link pending
tmb-20231231xex31d3.htm Edgar Link pending
tmb-20231231xex31d4.htm Edgar Link pending
tmb-20231231xex32d5.htm Edgar Link pending
tmb-20231231xex32d6.htm Edgar Link pending
tmb-20231231xex4d2.htm Edgar Link pending
tmb-20231231xex97.htm Edgar Link pending
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tmb-20231231_cal.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable